Drug
Elobixibat clinical trials
Also written A3309.
- studies test it
- 12
- open now
- 0
- in phase 3
- 3
- first study started
- 2009
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
12 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 2 |
| 2013 | 3 |
| 2015 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 6
- Phase 3
- 3
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 5
Ferring Pharmaceuticals (4) · Albireo (3) · Yokohama City University (3) · Michael Camilleri, MD (1) · International University of Health and Welfare (1)
Studies
Open first, then newest update. How each study uses elobixibat is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Phase 2 Study of Elobixibat in Adults With NAFLD or NASHCompletedPhase 2AlbireoNCT04006145Written as Elobixibat
- Study of A3309 in Patients With DyslipidemiaCompletedPhase 2AlbireoNCT01069783Written as A3309
- Elobixibat for Chronic Constipation Without Defecation DesireTerminatedPhase 4International University of Health and WelfareNCT05703464Written as Elobixibat 10mg
- Long-term Elobixibat for Chronic ConstipationStatus unknownPhase 4Yokohama City UniversityNCT04784780Written as Elobixibat 10mg
- Elobixibat for Chronic Constipation Without Defecation DesireStatus unknownPhase 4Yokohama City UniversityNCT05165199Written as Elobixibat 10mg
- Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver DiseaseCompletedPhase 2Yokohama City UniversityNCT04235205Written as Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)
- Effect of Ileal Bile Acid Transporter Inhibitor in Functional ConstipationCompletedPhase 2Michael Camilleri, MDNCT01038687Written as A3309
- Study of Elobixibat (A3309) in Patients With Chronic Idiopathic ConstipationCompletedPhase 2AlbireoNCT01007123Written as A3309
- Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic ConstipationCompletedPhase 3Ferring PharmaceuticalsNCT01895543Written as Elobixibat 10 mg
- Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic ConstipationTerminatedPhase 3Ferring PharmaceuticalsNCT01833065Written as Elobixibat 10 mg/day
- 26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic ConstipationTerminatedPhase 3Ferring PharmaceuticalsNCT01827592Written as Elobixibat 10 mg
- Elobixibat Colonic Motor Function StudyWithdrawnPhase 2Ferring PharmaceuticalsNCT02392546Written as elobixibat
Codes
What other systems call elobixibat · ClinicalTrials.gg INT006286
- MeSH (NLM) C581303elobixibatOne source NLM
- UNII (FDA) 865UEK4EJCELOBIXIBATConfirmed FDA, NLM, Wikidata
- Wikidata Q5367035elobixibatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171820ElobixibatOne source FDA
- DrugBank DB12486One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C581303 | elobixibat | One source NLM |
| UNII (FDA) | 865UEK4EJC | ELOBIXIBAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5367035 | elobixibat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171820 | Elobixibat | One source FDA |
| DrugBank | DB12486 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.